Venture Capital

MassBio Recognizes Three Biotech and Pharma Companies with Awards at Annual State of Possible Conference

April 25, 2024

Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology

April 18, 2024

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

April 9, 2024

New England Biolabs Leases 28,000 SF

December 7, 2020

Walgreens Boots Alliance Appoints Bryan C. Hanson to Board of Directors

October 28, 2022

Immunology biotech firm to relocate from Cambridge to Woburn

November 18, 2021

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing

Bruker to Acquire the NanoString Business in an Asset Deal

Plastic Degradation Company, Breaking, Emerges from Stealth with Naturally-Derived Solution to Degrade Multiple Plastics with $10.5M in Seed Funding

Exowatt Launches with $20 Million to Modernize Data Center Power for the AI Era

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Most Read

MassBio Recognizes Three Biotech and Pharma Companies with Awards at Annual State of Possible Conference

Tufts Medicine, Navvis Partner to Accelerate Value-Based Care, Driving Healthcare Transformation in Massachusetts

athenahealth and the American Council of the Blind Collaborate to Expand Digital Accessibility for athenahealth Patients

Nature Publication Highlights the Benefits of Tropis® Intradermal When Used to Administer a First-in-Class Self-Amplifying mRNA Vaccine

EDITOR PICKS

MassBio Recognizes Three Biotech and Pharma Companies with Awards at Annual State of Possible Conference

Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

POPULAR POSTS

New England Biolabs Leases 28,000 SF

Walgreens Boots Alliance Appoints Bryan C. Hanson to Board of Directors

Immunology biotech firm to relocate from Cambridge to Woburn

POPULAR CATEGORY

ABOUT US

FOLLOW US